Phase I Study of Tomuzotuximab, a Glycoengineered Therapeutic Antibody Against the Epidermal Growth Factor Receptor, in Patients With Advanced Carcinomas
ESMO Open - United Kingdom
doi 10.1136/esmoopen-2017-000303
Full Text
Open PDFAbstract
Available in full text
Date
February 1, 2018
Authors
Publisher
BMJ